EX-99.1 2 ipa-ex99_1.htm EX-99.1 EX-99.1

 

Report of Voting Results

 

Submitted Pursuant to

Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations

In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") held on November 14, 2024, via live webcast (the "Meeting"). Each of the matters is described in greater detail in the Corporation's management information circular dated October 14, 2024 (the "Circular").

(a)
The number of directors was set at four. The following are the voting results on this matter:

FOR

% FOR

AGAINST

% AGAINST

Number of Directors  10,999,231

81.01%

2,578,940

18.99%

(b)
In the Circular, management of the Corporation proposed four nominees for election as directors of the Corporation for the ensuing year or until their successors are duly elected or appointed. The Corporation’s majority voting policy stipulates that any director nominee who receives more votes withheld than in favor must tender their resignation to the board. In this instance, Barry A. Springer did not achieve the required majority and, in accordance with the policy, submitted his resignation following the meeting. The board is now considering this resignation and will announce its decision within 90 days of the resignation, as per the company's governance guidelines. The following are the voting results on this matter:

FOR

%

FOR

WITHHELD

% WITHHELD

Jennifer L. Bath

7,841,725

66.87%

3,885,466

33.13%

Chris Buyse

9,251,399

78.89%

2,475,791

21.11%

Barry A. Springer

5,850,192

49.89%

5,876,998

50.11%

Dirk Witters

8,528,076

72.72%

3,199,114

27.28%

(c)
Grant Thornton LLP was reappointed as the Corporation's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:

FOR

%

FOR

WITHHELD

%

WITHHELD

Reappointment of Auditors

12,184,321

89.73%

1,393,851

10.27%

Dated this 15th day of November 2024.

IMMUNOPRECISE ANTIBODIES LTD.

By:

/s/ Kristin Taylor

Name:

Kristin Taylor

Title:

Chief Financial Officer

 

1